These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11971944)

  • 1. Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II.
    Boisfer E; Stengel D; Pastier D; Laplaud PM; Dousset N; Ninio E; Kalopissis AD
    J Lipid Res; 2002 May; 43(5):732-41. PubMed ID: 11971944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis.
    De Geest B; Stengel D; Landeloos M; Lox M; Le Gat L; Collen D; Holvoet P; Ninio E
    Arterioscler Thromb Vasc Biol; 2000 Oct; 20(10):E68-75. PubMed ID: 11031226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
    Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration.
    Forte TM; Oda MN; Knoff L; Frei B; Suh J; Harmony JA; Stuart WD; Rubin EM; Ng DS
    J Lipid Res; 1999 Jul; 40(7):1276-83. PubMed ID: 10393212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism.
    Hedrick CC; Hassan K; Hough GP; Yoo JH; Simzar S; Quinto CR; Kim SM; Dooley A; Langi S; Hama SY; Navab M; Witztum JL; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):1946-52. PubMed ID: 10938016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles.
    Castellani LW; Navab M; Van Lenten BJ; Hedrick CC; Hama SY; Goto AM; Fogelman AM; Lusis AJ
    J Clin Invest; 1997 Jul; 100(2):464-74. PubMed ID: 9218525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein A-II/A-I ratio is a key determinant in vivo of HDL concentration and formation of pre-beta HDL containing apolipoprotein A-II.
    Pastier D; Dugué S; Boisfer E; Atger V; Tran NQ; van Tol A; Chapman MJ; Chambaz J; Laplaud PM; Kalopissis AD
    Biochemistry; 2001 Oct; 40(41):12243-53. PubMed ID: 11591143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins.
    Tsimihodimos V; Kakafika A; Tambaki AP; Bairaktari E; Chapman MJ; Elisaf M; Tselepis AD
    J Lipid Res; 2003 May; 44(5):927-34. PubMed ID: 12611907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis.
    Boisfer E; Lambert G; Atger V; Tran NQ; Pastier D; Benetollo C; Trottier JF; Beaucamps I; Antonucci M; Laplaud M; Griglio S; Chambaz J; Kalopissis AD
    J Biol Chem; 1999 Apr; 274(17):11564-72. PubMed ID: 10206963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio.
    Navab M; Hama-Levy S; Van Lenten BJ; Fonarow GC; Cardinez CJ; Castellani LW; Brennan ML; Lusis AJ; Fogelman AM; La Du BN
    J Clin Invest; 1997 Apr; 99(8):2005-19. PubMed ID: 9109446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility.
    McCall MR; La Belle M; Forte TM; Krauss RM; Takanami Y; Tribble DL
    Biochim Biophys Acta; 1999 Jan; 1437(1):23-36. PubMed ID: 9931415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia.
    Escolà-Gil JC; Julve J; Marzal-Casacuberta A; Ordóñez-Llanos J; González-Sastre F; Blanco-Vaca F
    J Lipid Res; 2000 Aug; 41(8):1328-38. PubMed ID: 10946021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.
    Tsimihodimos V; Karabina SA; Tambaki AP; Bairaktari E; Goudevenos JA; Chapman MJ; Elisaf M; Tselepis AD
    Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):306-11. PubMed ID: 11834533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein.
    Graham A; Hassall DG; Rafique S; Owen JS
    Atherosclerosis; 1997 Dec; 135(2):193-204. PubMed ID: 9430369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis.
    Liberopoulos EN; Papavasiliou E; Miltiadous GA; Cariolou M; Siamopoulos KC; Tselepis AD; Elisaf MS
    Perit Dial Int; 2004; 24(6):580-9. PubMed ID: 15559488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect.
    Milionis HJ; Tambaki AP; Kanioglou CN; Elisaf MS; Tselepis AD; Tsatsoulis A
    Thyroid; 2005 May; 15(5):455-60. PubMed ID: 15929667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.
    Aviram M; Rosenblat M; Bisgaier CL; Newton RS; Primo-Parmo SL; La Du BN
    J Clin Invest; 1998 Apr; 101(8):1581-90. PubMed ID: 9541487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid.
    Kujiraoka T; Hattori H; Ito M; Nanjee MN; Ishihara M; Nagano M; Iwasaki T; Cooke CJ; Olszewski WL; Stepanova IP; Egashira T; Miller NE
    Atherosclerosis; 2004 Sep; 176(1):57-62. PubMed ID: 15306175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice.
    Tiniakou I; Kanaki Z; Georgopoulos S; Chroni A; Van Eck M; Fotakis P; Zannis VI; Kardassis D
    Atherosclerosis; 2015 Nov; 243(1):77-85. PubMed ID: 26363436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All ApoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified. Modulation of lipoprotein bioactivity by platelet-activating factor acetylhydrolase.
    Lee C; Sigari F; Segrado T; Hörkkö S; Hama S; Subbaiah PV; Miwa M; Navab M; Witztum JL; Reaven PD
    Arterioscler Thromb Vasc Biol; 1999 Jun; 19(6):1437-46. PubMed ID: 10364074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.